Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 786570, 8 pages
http://dx.doi.org/10.1155/2015/786570
Clinical Study

Increased Circulating Advanced Oxidation Protein Products and High-Sensitive Troponin T in Cirrhotic Patients with Chronic Hepatitis C: A Preliminary Report

1Department of Pharmaceutical Biochemistry, Wroclaw Medical University, 211 Borowska Street, 50556 Wroclaw, Poland
2Department of Physiology and Biochemistry, University of Physical Education, 35 Paderewskiego Avenue, 51612 Wroclaw, Poland
3Clinic of Infectious Diseases, Liver Diseases and Acquired Immune Deficiency, Wroclaw Medical University, 5 Koszarowa Street, 51149 Wroclaw, Poland

Received 23 July 2015; Revised 29 October 2015; Accepted 4 November 2015

Academic Editor: Hua Zhu

Copyright © 2015 Jolanta Zuwala-Jagiello et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Matsumori, Y. Matoba, and S. Sasayama, “Dilated cardiomyopathy associated with hepatitis C virus infection,” Circulation, vol. 92, no. 9, pp. 2519–2525, 1995. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Okabe, K. Fukuda, K. Arakawa, and M. Kikuchi, “Chronic variant of myocarditis associated with hepatitis C virus infection,” Circulation, vol. 96, no. 1, pp. 22–24, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Matsumori, C. Yutani, Y. Ikeda, S. Kawai, and S. Sasayama, “Hepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy,” Laboratory Investigation, vol. 80, no. 7, pp. 1137–1142, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Matsumori, “Hepatitis C virus infection and cardiomyopathies,” Circulation Research, vol. 96, no. 2, pp. 144–147, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Pozzi, E. Redaelli, L. Ratti et al., “Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases,” Minerva Gastroenterologica e Dietologica, vol. 51, no. 2, pp. 179–186, 2005. View at Google Scholar · View at Scopus
  6. S. Møller and J. H. Henriksen, “Cirrhotic cardiomyopathy,” Journal of Hepatology, vol. 53, no. 1, pp. 179–190, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Pozzi, S. Carugo, G. Boari et al., “Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites,” Hepatology, vol. 26, no. 5, pp. 1131–1137, 1997. View at Google Scholar · View at Scopus
  8. R. F. Lee, T. K. Glenn, and S. S. Lee, “Cardiac dysfunction in cirrhosis,” Best Practice & Research: Clinical Gastroenterology, vol. 21, no. 1, pp. 125–140, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. G. Fede, G. Privitera, T. Tomaselli, L. Spadaro, and F. Purrello, “Cardiovascular dysfunction in patients with liver cirrhosis,” Annals of Gastroenterology, vol. 28, no. 1, pp. 31–40, 2015. View at Google Scholar · View at Scopus
  10. R. D. Kociol, P. S. Pang, M. Gheorghiade, G. C. Fonarow, C. M. O'Connor, and G. M. Felker, “Troponin elevation in heart failure: prevalence, mechanisms, and clinical implications,” Journal of the American College of Cardiology, vol. 56, no. 14, pp. 1071–1078, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Olivetti, R. Abbi, F. Quaini et al., “Apoptosis in the failing human heart,” The New England Journal of Medicine, vol. 336, no. 16, pp. 1131–1141, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Wiese, C. Mortensen, J. P. Gøtze et al., “Cardiac and proinflammatory markers predict prognosis in cirrhosis,” Liver International, vol. 34, no. 6, pp. e19–e30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. B. M. Everett, N. R. Cook, M. C. Magnone et al., “Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the women's health study,” Circulation, vol. 123, no. 24, pp. 2811–2818, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. O. Bergmann, R. D. Bhardwaj, S. Bernard et al., “Evidence for cardiomyocyte renewal in humans,” Science, vol. 324, no. 5923, pp. 98–102, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. Z. J. Guo, H. X. Niu, F. F. Hou et al., “Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway,” Antioxidants and Redox Signaling, vol. 10, no. 10, pp. 1699–1712, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. J. Valente, T. Yoshida, R. A. Clark, P. Delafontaine, U. Siebenlist, and B. Chandrasekar, “Advanced oxidation protein products induce cardiomyocyte death via Nox2/Rac1/superoxide-dependent TRAF3IP2/JNK signaling,” Free Radical Biology & Medicine, vol. 60, pp. 125–135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Li, X. Qu, and A. M. Schmidt, “Sp1-binding elements in the promoter of RAGE are essential for amphoterin-mediated gene expression in cultured neuroblastoma cells,” The Journal of Biological Chemistry, vol. 273, no. 47, pp. 30870–30878, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Mustapha, A. Kirshner, D. De Moissac, and L. A. Kirshenbaum, “A direct requirement of nuclear factor-κ B for suppression of apoptosis in ventricular myocytes,” American Journal of Physiology: Heart and Circulatory Physiology, vol. 279, no. 3, pp. H939–H945, 2000. View at Google Scholar · View at Scopus
  19. Z.-M. Zhong, L. Bai, and J.-T. Chen, “Advanced oxidation protein products inhibit proliferation and differentiation of rat osteoblast-like cells via NF-κB pathway,” Cellular Physiology and Biochemistry, vol. 24, no. 1-2, pp. 105–114, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. Q. Zhou, S. Wu, J. Jiang et al., “Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients,” Nephrology, vol. 17, no. 7, pp. 642–649, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Kaneda, J. Taguchi, K. Ogasawara, T. Aizawa, and M. Ohno, “Increased level of advanced oxidation protein products in patients with coronary artery disease,” Atherosclerosis, vol. 162, no. 1, pp. 221–225, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Šebeková, V. Kupčová, R. Schinzel, and A. Heidland, “Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis—amelioration by liver transplantation,” Journal of Hepatology, vol. 36, no. 1, pp. 66–71, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Vassalle, S. Masini, F. Bianchi, and G. C. Zucchelli, “Evidence for association between hepatitis C virus seropositivity and coronary artery disease,” Heart, vol. 90, no. 5, pp. 565–566, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Kawano, S. Kawai, T. Nishijo, T. Shirai, Y. Inagaki, and R. Okada, “An autopsy case of hypertrophic cardiomyopathy with pathological findings suggesting chronic myocarditis,” Japanese Heart Journal, vol. 35, no. 1, pp. 95–105, 1994. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Barsotti, P. Fabbi, M. Fedele et al., “Role of advanced oxidation protein products and Thiol ratio in patients with acute coronary syndromes,” Clinical Biochemistry, vol. 44, no. 8-9, pp. 605–611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Deswal, N. J. Petersen, A. M. Feldman, J. B. Young, B. G. White, and D. L. Mann, “Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST),” Circulation, vol. 103, no. 16, pp. 2055–2059, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. H. Drazner, J. E. Rame, E. K. Marino et al., “Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study,” Journal of the American College of Cardiology, vol. 43, no. 12, pp. 2207–2215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Wencker, M. Chandra, K. Nguyen et al., “A mechanistic role for cardiac myocyte apoptosis in heart failure,” The Journal of Clinical Investigation, vol. 111, no. 10, pp. 1497–1504, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Malagarie-Cazenave, N. Andrieu-Abadie, B. Ségui et al., “Sphingolipid signalling: molecular basis and role in TNF-alpha-induced cell death,” Expert Reviews in Molecular Medicine, vol. 4, no. 28, pp. 1–15, 2002. View at Google Scholar · View at Scopus
  30. D. L. Mann, “Recent insights into the role of tumor necrosis factor in the failing heart,” Heart Failure Reviews, vol. 6, no. 2, pp. 71–80, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. M. S. Finkel, C. V. Oddis, T. D. Jacob, S. C. Watkins, B. G. Hattler, and R. L. Simmons, “Negative inotropic effects of cytokines on the heart mediated by nitric oxide,” Science, vol. 257, no. 5068, pp. 387–389, 1992. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Yokoyama, L. Vaca, R. D. Rossen, W. Durante, P. Hazarika, and D. L. Mann, “Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart,” Journal of Clinical Investigation, vol. 92, no. 5, pp. 2303–2312, 1993. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Yokoyama, M. Nakano, J. L. Bednarczyk, B. W. McIntyre, M. Entman, and D. L. Mann, “Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes,” Circulation, vol. 95, no. 5, pp. 1247–1252, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Nakamura, K. Fushimi, H. Kouchi et al., “Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II,” Circulation, vol. 98, no. 8, pp. 794–799, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Che, B. Liu, F. Nie et al., “Association of TNF-α with left ventricular diastolic dysfunction in patients with hepatitis C virus infection,” International Journal of Cardiology, vol. 168, no. 3, pp. 2903–2904, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Liu and S. S. Lee, “Nuclear factor-κB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy,” Liver International, vol. 28, no. 5, pp. 640–648, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Zuwała-Jagiełło, M. Pazgan-Simon, K. Simon, and M. Warwas, “Advanced oxidation protein products and inflammatory markers in liver cirrhosis: a comparison between rece and HCV-related cirrhosis,” Acta Biochimica Polonica, vol. 58, no. 1, pp. 59–65, 2011. View at Google Scholar
  38. T. Tsutamoto, C. Kawahara, M. Yamaji et al., “Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure,” European Journal of Heart Failure, vol. 11, no. 7, pp. 653–658, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Ellis, A. W. Dreisbach, and J. J. L. Lertora, “Plasma elimination of cardiac troponin I in end-stage renal disease,” Southern Medical Journal, vol. 94, no. 10, pp. 993–996, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Y.-M. Wang and K.-N. Lai, “Use of cardiac biomarkers in end-stage renal disease,” Journal of the American Society of Nephrology, vol. 19, no. 9, pp. 1643–1652, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. L. K. Newby, R. L. Jesse, J. D. Babb et al., “ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents,” Journal of the American College of Cardiology, vol. 60, no. 23, pp. 2427–2463, 2012. View at Google Scholar
  42. M. N. Fahie-Wilson, D. J. Carmichael, M. P. Delaney, P. E. Stevens, E. M. Hall, and E. J. Lamb, “Cardiac troponin T circulates in the free, intact form in patients with kidney failure,” Clinical Chemistry, vol. 52, no. 3, pp. 414–420, 2006. View at Publisher · View at Google Scholar · View at Scopus